Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303472 | 1.00 | PTGS2 (0.47) | PTGS2DGAT1ADORA3ALDH1A1POLB | |
| SCHEMBL1399597 | 0.81 | HCRTR2 (0.38) | DGAT1ALDH1A1MAPT | |
| SCHEMBL14113476 | 0.81 | HCRTR2 (0.38) | DGAT1ALDH1A1MAPT | |
| SCHEMBL1399596 | 0.81 | HCRTR2 (0.38) | DGAT1ALDH1A1MAPT | |
| SCHEMBL27731989 | 0.79 | DGAT1 (0.47) | DGAT1ADORA3ALDH1A1POLBMAPT | |
| SCHEMBL1399671 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBMAPTMEN1KMT2A | |
| SCHEMBL1399672 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBMAPTMEN1KMT2A | |
| SCHEMBL4619399 | 0.77 | SLC18A3 (0.46) | DGAT1ALDH1A1POLBMAPTSLC18A3 | |
| SCHEMBL3543093 | 0.77 | MAPT (0.63) | ALDH1A1POLBMAPTSLC18A3SLC6A3 | |
| SCHEMBL3543089 | 0.77 | MAPT (0.63) | ALDH1A1POLBMAPTSLC18A3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2120911-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | Prosidion Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | PTGS2 1549/4885DGAT1 84/4885ADORA3 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.